Product name
Recombinant Human DES1-3 IGF-1 protein
Code
CD01919
Biological activity
Fully biologically active when compared to standard. The ED50 as determined by a cell proliferation assay using serum free human MCF-7 cells is less than 2 ng/ml, corresponding to a specific activity of > 5.0 × 105 IU/mg.
Endotoxin
Less than 50 EU/mg of rHuDES1-3 IGF-1 as determined by LAL method.
Synonyms
DES1-3 IGF-1,IGF; MGF; IGFI; IGF-I, Human
Sequence
TLCGAELVDA LQFVCGDRGF YFNKPTGYGS SSRRAPQTGI VDECCFRSCD LRRLEMYCAP LKPAKSA
Uniprot Accession
Molecular Weight
Approximately 7.4 kDa, a single non-glycosylated polypeptide chain containing 67 amino acids.
Formulation
Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4.
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
Background
IGF-1 belonged to the insulin gene family, is a mitogenic polypeptide growth factor that stimulates the proliferation and survival of various cell types including muscle, bone, and cartilage tissue in vitro. DES(1-3)IGF-1, is a truncated variant of human IGF-1 with the tripeptide Gly-Pro-Glu absent from the N-terminus. It has been isolated from bovine colostrum, human brain and porcine uterus. The DES(1-3)IGF-1 probably results from post-translational cleavage of IGF-1. It has about 10-fold more potent than IGF-I at stimulating hypertrophy and proliferation of cultured cells, a consequence of much reduced binding to IGF-binding proteins, in turn caused by the absence of the glutamate at position 3. Clinical opportunities for DES(1-3)IGF-1 have not yet been evaluated, but could apply in catabolic states as well as for the treatment of inflammatory bowel diseases.
Storage
-20ºC
Research area
Immunology
